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Mesenchymal stem cells (MSCs), especially those derived from syno-
vium, are an attractive cell source for meniscus regeneration, because
synovial MSCs have remarkable proliferation and chondrogenic
potential. We previously reported that intraarticular injection of syno-
vial MSCs promoted meniscal regeneration in a rat model. It was a
syngeneic transplantation model; therefore, possible immune reactions
seem to be negligible. We compared the effect of syngeneic and allo-
geneic transplantation of synovial mesenchymal stem cells (MSCs) for
meniscus regeneration in a rat model.
Synovium was harvested from the knee joints of 3 strains of rats, F344,
Lewis, and ACI. The anterior half of themedial meniscus in both knees of
F344 rats was removed and 5 million synovial MSCs of 3 strains were
injected into the right knee of F344 rats. F344 MSC transplantation is
regarded as a syngeneic model, Lewis MSC transplantation as a minor
mismatched model, and ACI MSC transplantation as a major mis-
matched model.
At 4 weeks, the area of the regenerated meniscus in the F344 and
Lewis groups was signiﬁcantly larger than that in the ACI group (n ¼
5; p < 0.05). Histological score was signiﬁcantly better in the F344
group than in the ACI group at 4 weeks (n ¼ 5; p < 0.05), and sig-
niﬁcantly better in the F344 and Lewis groups than in the ACI group at
8 weeks (n ¼ 4; p < 0.05). One week after DiI labeled MSCs were
transplanted, DiI positive area in the syngeneic group was larger than
in the ACI group. The number of ED1 positive macrophage in the
synovium signiﬁcantly increased in the ACI group than in the F344
group (n ¼ 4; p < 0.05). The number of CD8 positive T cells in the
synovium also increased in the ACI group than in the F344 group (n ¼
4; p < 0.05).
Syngeneic and minor mismatched transplantation of synovial MSCs
promoted meniscus regeneration better than major mismatched
transplantation in a rat meniscectmized model. Synovial MSCs were
rejected by immune reaction in a major mismatched transplantation. If
allogeneic synovial MSCs are used for meniscal regeneration in a clinical
situation, their histocompatibility antigens should be closer to those of
the recipient.
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PELVIS IS SUPERIOR TO FEMUR AND TIBIA AS A SOURCE FOR
MINIMALLY MANIPULATED MESENCHYMAL STEM CELLS
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Purpose: Since their description in 1999 mesenchymal stem cells
(MSCs) has been intensively investigated for the treatment of a variety
of musculoskeletal conditions. Whilst a large amount of pre-clinical
work has been undertaken this has yet to be translated into a widely
used or accepted clinical treatment for use in orthopedic conditions.
The evolving nature of our understanding of MSCs and their actions
means that there is also a lack of information as to the mechanism of
action of some of the effects of MSCs that have been demonstrated. The
high cost of laboratory based techniques and developing knowledge
about the paracrine actions of MSCs has led to increased interest in the
use of so-called single sitting orthopedic procedures where MSCs are
harvested from an individual and re-implanted at the site of injury in
one sitting.
In orthopedic surgery the obvious site to harvest MSCs from is bone
marrow given the ease of access for orthopedicsurgeons. However, the relatively low number of MSCs found in bone
marrow means that yields are low. Previous work has demonstrated
that MSCs can be harvested from a variety of different bones including
the pelvis, femur, humerus, tibia, and calcaneus. The pelvis is currently
the gold standard site for harvesting bone marrow for use in procedures
such as cartilage repair of the knee. However, harvesting from the pelvis
results in a second operative site and thus increasedmorbidity. We have
therefore sought to determine if bone marrow harvested from either
the tibia or the femur can provide MSCs in comparable amounts to that
obtained from the pelvis.
Methods: Samples were obtained from patients undergoing knee
arthroplasty. Participants provided informed consent and approval
was obtained from the local Research Ethics Committee. An 8G
Jamshidi biopsy needle and syringe were used to obtain bone mar-
row samples from the pelvis, femur, and tibia of each individual.
Samples were taken before any surgical procedure was carried out on
the long bones. A maximum of 10 mls of bone marrow was sampled to
avoid dilution of the bone marrow with peripheral blood. Samples
were placed in EDTA coated tubes and transported to the laboratory
immediately.
The mononuclear cellular layer was extracted using a density cen-
trifugation technique. A total cell count was then
performed using a Millipore ScepterTM. 2 x 106 cells were removed
from the sample to undertake colony-forming unit- ﬁbroblast (CFU-F)
count assessments in duplicate and the remaining cells seeded into a
tissue culture ﬂask. All cells were fed with Invitrogen MesenPro RSTM
media every 2-3 days.
CFU-F cells were ﬁxed at day 14 and stained with Giemsa stain to
allow colony counting. Colonies were counted if they were >1mm in
diameter. Cells were passaged when they reached 70-80% conﬂuence
and population-doubling information was recorded at each passage up
to the end of passage three.
Results: The graphs below show the initial cell yield, CFU-F count,
and sample doubling time for the ﬁrst 10 individuals (Male to
female ratio 6:4, mean age ¼ 64.2 yrs, range ¼ 52 - 77 yrs). N is less
than 10 in some groups due to failure of cells to expand in culture.
Missing data for 4 individuals for doubling times (where one site
failed to grow in culture) was imputed using the multiple imputa-
tion by chained equations method in Stata 12. All other statistical
analyses was carried out using GraphPad Prism 6. ANOVA tests
showed a signiﬁcant difference (p < 0.05) in initial cell yield and
CFU-F count between the different sites sampled but no signiﬁcant
difference in doubling times. These results show that despite the
presence of MSCs in all bone marrow the samples obtained from the
pelvis were superior in both number of cells obtained and CFU-F
count.
